PD-L1 tumor expression determined by immunohistochemistry (IHC) or the percentage of tumor-infiltrating lymphocytes (TILs) was not found to be associated with the response to anti-PD-L1 agents [30,31]. This evidence concerns the gene CD274 and neoplasm.